<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Patients with <z:mp ids='MP_0002055'>diabetes</z:mp> remain at high risk for cardiovascular events despite aggressive blood pressure, <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>, and blood <z:chebi fb="105" ids="17234">glucose</z:chebi> control </plain></SENT>
<SENT sid="1" pm="."><plain>We identified prevalence and predictors of <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo>, characterized current <z:chebi fb="23" ids="18059">lipid</z:chebi> therapy, and estimated the theoretical benefit of more effective <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>-raising methods among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We analyzed a primary care-based population of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 7,692) in 12 eastern Massachusetts outpatient practices </plain></SENT>
<SENT sid="3" pm="."><plain>We grouped fibrates, niacins, and n-3 fatty acid preparations as nonstatin <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>-raising medicines, and we used published studies to estimate the potential benefit of raising <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels in this population </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Nearly half (49.5%) of patients had <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> (&lt;40 mg/dl for men, &lt;50 mg/dl for women) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0003233'>Low HDL cholesterol</z:hpo> was independently associated with prevalent <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>), younger age, and higher A1C levels </plain></SENT>
<SENT sid="6" pm="."><plain>Nearly two-thirds of patients (63.0%) were prescribed a <z:chebi fb="0" ids="35664">statin</z:chebi> (67.6% of patients below the <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> goal, 80.5% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, only 7.9% of patients were prescribed a nonstatin <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>-raising medication, including 16.4% of patients below the <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> goal with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Based on published studies, normalizing <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> in this primary care cohort would correspond to an estimated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality reduction of 42% in women and 23% in men </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Nearly half of the patients in this large primary care cohort had <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> levels </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast to frequent <z:chebi fb="0" ids="35664">statin</z:chebi> use, few patients were prescribed currently available medicines to raise <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0003233'>Low HDL cholesterol</z:hpo> represents a highly prevalent and potentially modifiable risk factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> prevention in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>